MET先锋派 | 扬帆起航,卡马替尼助推METex14跳突晚期NSCLC一线治疗迈入新征程
Editorial Office of Chinese Journal of Lung Cancer,[Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutati
Editorial Office of Chinese Journal of Lung Cancer,[Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutati
肺癌新药一直是临床研发重点,不断涌现的新药以及新疗法为肺癌患者带来了更多希望。时值年终岁末,在此对本年度肺癌领域15种获批新药以及获批新适应症进行逐一盘点,供肺癌患者和家属参考。